Loading clinical trials...

TERMINATEDPHASE2

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

A Phase Iia, Multicenter, Treatment Assigned, Open-label, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Japanese Subjects With Mild To Moderate Alzheimer's Disease

NCT01238991•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind studies.

Eligibility

Age

52 - 87 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Screening brain MRI scan is consistent with the diagnosis of AD.
•MMSE score 10 and above.

Exclusion Criteria

•Significant neurological diseases other than AD.
•Brain MRI evidence of vasogenic edema during the preceding studies.
•Clinically significant illness.

Locations (11)

Meitetsu Hospital

Nagoya, Aichi-ken, Japan

Ibaraki Prefectural Central Hospital

Kasama, Ibaraki, Japan

Shonan Atsugi Hospital

Atsugi, Kanagawa, Japan

Kitasato University East Hospital

Sagamihara-shi, Kanagawa, Japan

Suwa Red Cross Hospital

Suwa, Nagano, Japan

Tazuke Kofukai Medical Research Institute Kitano Hospital

Osaka, Osaka, Japan

Osaka Medical College Hospital

Takatsuki, Osaka, Japan

Juntendo University Hospital

Bunkyo-ku, Tokyo, Japan

Juntendo Tokyo Koto Geriatric Medical Center

Koto-ku, Tokyo, Japan

The Tokyo Jikei University School of Medicine

Minato-ku, Tokyo, Japan

Key Dates

Start Date

December 1, 2010

Primary Completion Date

December 1, 2013

Completion Date

December 1, 2013

Last Updated

December 22, 2014

Enrollment

ACTUAL participants

Conditions

Alzheimer's Disease

Interventions

ACC-001

BIOLOGICAL

ACC-001

BIOLOGICAL

ACC-001

BIOLOGICAL

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 22, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia